Cargando…

Treatment and re-treatment results of HCV patients in the DAA era

BACKGROUND: Re-treatment in patients with a chronic hepatitis C virus (HCV) infection and a previous failure to direct-acting antiviral (DAA) treatment remains a challenge. Therefore, we investigated the success rate of treatment and re-treatment regimens used at our center from October 2011 to Marc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piecha, Felix, Gänßler, Jan-Michael, Ozga, Ann-Kathrin, Wehmeyer, Malte H., Dietz, Julia, Kluwe, Johannes, Laschtowitz, Alena, von Felden, Johann, Sterneck, Martina, Jordan, Sabine, Pischke, Sven, Lohse, Ansgar W., Schulze zur Wiesch, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200014/ https://www.ncbi.nlm.nih.gov/pubmed/32369527 http://dx.doi.org/10.1371/journal.pone.0232773

Ejemplares similares

Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
por: Piecha, Felix, et al.
Publicado: (2019)

Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
por: Drolz, Andreas, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern
por: Wehmeyer, Malte H., et al.
Publicado: (2016)

Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis
por: Wehmeyer, Malte H., et al.
Publicado: (2022)

The Clinical Perspective on Hepatitis E
por: Horvatits, Thomas, et al.
Publicado: (2019)

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
por: Koop, Anja Christina, et al.
Publicado: (2020)

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort
por: Bockmann, Jan-Hendrik, et al.
Publicado: (2020)

Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
por: Wehmeyer, Malte H, et al.
Publicado: (2014)

Erratum zu: Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial
por: Wehmeyer, Malte H., et al.
Publicado: (2022)

Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D
por: Hermanussen, Lennart, et al.
Publicado: (2023)

Factors associated with long-term survival after liver transplantation: A retrospective cohort study
por: Pischke, Sven, et al.
Publicado: (2017)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A
por: Brehm, Thomas Theo, et al.
Publicado: (2021)

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients
por: Ruether, Darius F., et al.
Publicado: (2022)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules
por: Ackermann, Christin, et al.
Publicado: (2019)

Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival
por: Piecha, Felix, et al.
Publicado: (2019)

Characterization of the immune cell landscape of patients with NAFLD
por: Diedrich, Tom, et al.
Publicado: (2020)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
por: Beisel, Claudia, et al.
Publicado: (2014)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
por: Salmon, Dominique, et al.
Publicado: (2018)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment
por: Amer, Fatma, et al.
Publicado: (2019)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
por: Tayyab, Ghias Un Nabi, et al.
Publicado: (2020)

Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave
por: Herting, Anna, et al.
Publicado: (2023)

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach
por: Li, Wei, et al.
Publicado: (2020)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2l5lr91cfgootjmoqkf7ktl28v